Cystic fibrosis–related diabetes (CFRD) is a distinct, often underdiagnosed comorbidity that affects approximately 20 percent of adolescents and 40 to 50 percent of adults living with cystic fibrosis. Unlike type 1 or type 2 diabetes, CFRD results from a unique combination of insulin deficiency caused by progressive pancreatic damage and intermittent insulin resistance driven by chronic inflammation and corticosteroid use. Managing CFRD demands highly specialized, multidisciplinary care that integrates pulmonary, nutritional, and endocrine expertise. Yet despite major advances in cystic fibrosis treatments and diabetes management, significant disparities in healthcare access persist. These inequities—rooted in socioeconomic status, geography, race, ethnicity, and healthcare system design—create avoidable gaps in diagnosis, treatment, and outcomes. Addressing these disparities is not only a matter of clinical necessity but also of fundamental health equity for all patients with cystic fibrosis and diabetes.

The Scope of Disparities in CFRD Care

Healthcare disparities refer to systematic, preventable differences in the access to, quality of, and outcomes from healthcare services across different population groups. For CFRD patients, these disparities manifest in delayed screening, inconsistent access to endocrinology consultations, variable adherence to treatment guidelines, and worse glycemic control. Research published by the Cystic Fibrosis Foundation shows that non-white individuals with cystic fibrosis are less likely to receive recommended diabetes screening and have higher rates of pulmonary exacerbations and mortality. Similarly, adults with CF who live in rural areas often travel hundreds of miles to reach an accredited cystic fibrosis care center, and many lack access to specialized dietitians and diabetes educators essential for CFRD management. The problem is not simply one of individual behavior or disease severity; it is deeply embedded in the structural fabric of healthcare delivery.

Racial and Ethnic Disparities

Hispanic and Black individuals with CF have lower odds of receiving annual oral glucose tolerance tests, experience greater delays in CFRD diagnosis, and show higher HbA1c levels even after controlling for disease severity. Data from the CFF Patient Registry consistently indicates that minority patients are less likely to be prescribed advanced diabetes technologies such as continuous glucose monitors or insulin pumps. These disparities persist even within the same care centers, suggesting that implicit bias and cultural barriers play a significant role. A 2022 study in Pediatric Pulmonology found that Hispanic children with CF were 30 percent less likely to have a documented endocrinology visit in the previous year compared to non-Hispanic white children, despite similar disease characteristics.

Socioeconomic Disparities

Financial constraints create a cascade of obstacles for CFRD management. Patients from lower-income households are more likely to miss clinic appointments, ration medications, and lack continuous health insurance coverage—all of which directly compromise glycemic control. Even patients with health insurance may face high copays for endocrinologist visits, continuous glucose monitors, or insulin pumps. Those without coverage often forgo needed supplies, leading to dangerous gaps in therapy. A study in the Journal of Cystic Fibrosis found that uninsured CF patients had significantly lower rates of insulin therapy initiation compared to insured peers. Prescription drug costs, transportation expenses, and lost wages from frequent appointments compound the burden. For CFRD specifically, the need for carbohydrate counting and frequent blood glucose monitoring demands time and resources that low-wage workers can ill afford. Food insecurity further complicates dietary management, as patients may lack consistent access to the balanced meals needed to stabilize blood sugar.

Geographic Disparities

The Cystic Fibrosis Foundation requires accredited care centers to offer comprehensive multidisciplinary services, including endocrinology, nutrition counseling, and social work. These centers, however, are concentrated in large urban hospitals. Patients living in rural counties may face round trips exceeding 200 miles to reach their nearest center. Telemedicine has emerged as a partial solution, but broadband access remains uneven. A 2021 analysis indicated that 28 percent of rural CF patients lacked reliable internet, limiting virtual visits for diabetes education and insulin dose adjustments. Furthermore, local primary care providers often lack familiarity with CFRD guidelines, leading to suboptimal co-management. In many rural areas, there is no endocrinologist within a 50-mile radius, forcing patients to rely on general practitioners who may never have treated a single case of CFRD.

Adolescents transitioning from pediatric to adult care face unique vulnerabilities. During this period, care coordination often breaks down, interrupting diabetes monitoring and insulin therapy. Young adults may lose their pediatric endocrinologist before an adult provider is secured, resulting in months without specialized care. The CFF reports that transition-aged patients (18–25 years) have higher rates of hospitalization and lower rates of annual diabetes screening compared to older adults. For CFRD, this transition is particularly risky because insulin requirements often change during late adolescence due to growth, hormonal shifts, and changes in pulmonary health. Without seamless handoffs, patients may experience rapid deterioration in glycemic control and lung function.

Root Causes of Disparities

The roots of healthcare disparities in CFRD are multifactorial, interwoven with broader social determinants of health. Understanding each contributing factor is essential for designing effective interventions.

Healthcare System Fragmentation

The fragmented nature of US healthcare poses unique challenges for CFRD patients, who must coordinate between pulmonary, endocrine, and primary care providers. Many cystic fibrosis centers lack embedded endocrinologists, forcing patients to make separate appointments at different locations. This not only increases travel burden but also leads to fragmented communication between specialists. Prior authorization requirements for insulin formulations or glucose monitors can cause treatment delays lasting weeks. In safety-net hospitals, high caseloads and limited interpreter services further strain care quality. A lack of standardized screening protocols across centers also contributes to variable detection rates: some programs screen annually with oral glucose tolerance tests; others rely on random glucose checks, which miss early CFRD. The CFF has attempted to standardize care through its annual guidelines, but compliance remains uneven, particularly at smaller centers with fewer resources.

Cultural and Language Barriers

Effective CFRD management requires ongoing communication about dietary adjustments, insulin dosing, and symptom recognition. Language discordance between patients and clinicians has been linked to lower medication adherence and higher emergency department use. Hispanic CF patients, for instance, are less likely to receive diabetes education in Spanish, worsening health literacy gaps. Cultural norms around food, illness causation, and medication use can also influence treatment acceptance. Without culturally competent care teams, patients may distrust recommendations or feel alienated from the care process. Even well-intentioned providers may inadvertently use jargon that confuses patients with limited health literacy. Plain-language educational materials and the use of professional medical interpreters are essential but often underutilized in CF clinics.

Insurance and Policy Barriers

The United States’ reliance on employer-sponsored insurance creates instability for many CF patients, who often cannot maintain full-time employment due to illness burden. Medicaid expansion has improved coverage rates in some states, but the 10 states that have not expanded Medicaid leave many low-income adults without affordable options. For CFRD patients, coverage gaps can mean losing access to insulin, continuous glucose monitors, and specialized care. Medicare coverage for diabetes supplies is also complex, with separate Part B and Part D rules that confuse patients and providers alike. The CFF advocates for policies that ensure continuous insurance coverage, prohibition of step therapy for CF-related medications, and funding for the federal 340B drug discount program, which helps safety-net providers afford insulin and supplies. Yet these policy solutions face ongoing political hurdles.

Clinical Consequences of Disparities

Disparities in CFRD access do not merely inconvenience patients—they have measurable, serious consequences for disease progression and survival.

Delayed Diagnosis and Accelerated Lung Decline

CFRD often develops insidiously, with symptoms such as weight loss, fatigue, and frequent infections overlapping with CF itself. Without regular screening, diagnosis is frequently delayed by two to three years. During this time, untreated hyperglycemia accelerates lung function decline, increases pulmonary exacerbation frequency, and worsens nutritional status. Studies show that for every 1 percent increase in HbA1c, forced expiratory volume in one second (FEV1) declines by an additional 5 to 10 percent. Minority populations and uninsured patients experience the longest delays between onset and diagnosis. A retrospective analysis of CFF registry data found that Black patients were diagnosed with CFRD an average of 1.8 years later than white patients, even after adjusting for age and lung function.

Increased Mortality and Transplantation Rates

CFRD already confers a much increased risk of mortality compared to CF alone. When disparities lead to delayed insulin initiation or poor glycemic control, the risk compounds. Data from the CFF Patient Registry indicate that Black and Hispanic individuals with CFRD have a hazard ratio for death approximately 1.5 times higher than their white counterparts after adjusting for disease severity. Similarly, patients from low-income neighborhoods have higher rates of lung transplantation and death before age 30. These grim statistics reflect systemic barriers, not intrinsic disease differences. The mechanisms are clear: hyperglycemia promotes chronic inflammation, increases the risk of bronchial infection with Pseudomonas aeruginosa, and worsens nutritional depletion—all of which accelerate the need for transplant and shorten survival.

Strategies to Reduce Disparities

Eliminating disparities in CFRD care requires coordinated action at the policy, institutional, community, and individual levels. Several evidence-based strategies have shown promise and can be scaled.

Expanding Telemedicine and Digital Health

The rapid adoption of telehealth during the COVID-19 pandemic demonstrated its potential to bridge geographic gaps. For CFRD, tele-endocrinology consultations, remote glucose monitoring, and virtual nutrition therapy can reduce travel burdens while maintaining care quality. Programs like the CFF-sponsored telemedicine initiative have improved access for rural patients. A 2021 pilot study found that virtual visits for CFRD management led to HbA1c reductions comparable to in-person care, with high patient satisfaction. However, to avoid creating new digital divides, initiatives must include device lending programs and broadband subsidies for low-income patients. Hybrid models that alternate in-person and virtual visits may be ideal for preserving trust and physical assessments while offering convenience.

Enhancing Provider Training and Support

Many primary care providers and pediatricians in underserved areas have never managed CFRD. Training programs that offer continuing education credits, tele-mentoring with CF specialists (the Project ECHO model), and dissemination of pocket guidelines can raise baseline competence. The CFF also offers online courses on CFRD management that are free to all clinicians. Equally important is training in cultural humility and implicit bias, so that all patients receive respectful, patient-centered communication. Institutions should conduct regular equity audits to identify disparities in their own clinics—for example, tracking rates of diabetes screening by race and insurance status, then implementing targeted interventions if gaps are found.

Community Outreach and Culturally Tailored Education

Patient education must be culturally tailored and linguistically accessible. The Cystic Fibrosis Foundation offers Spanish-language materials on CFRD, but more can be done with community health workers. Peer support programs—connecting newly diagnosed CFRD patients with experienced mentors from similar backgrounds—have shown success in improving self-management and clinic attendance. Mobile health units that offer point-of-care A1c testing and insulin teaching at CF community events can reach patients who are disconnected from formal care. For example, the Chicago CF Care Center piloted a mobile outreach program that increased screening rates among Latino patients by 40 percent over two years. Partnering with patient advocacy groups like the CFRD Alliance can amplify these efforts and ensure materials resonate with diverse audiences.

Policy and Advocacy at Scale

Systemic change requires advocacy at the state and federal level. Expanding Medicaid in non-expansion states would automatically cover more low-income CF patients. The CFF advocates for policies that ensure continuous insurance coverage, prohibition of step therapy for CF-related medications, and funding for the federal 340B drug discount program, which helps safety-net providers afford insulin and supplies. At the institutional level, healthcare systems should eliminate copays for annual diabetes screening and fund interpreter services adequately. Clinical registries should stratify outcomes by race, ethnicity, and socioeconomic status to spur accountability. The CFF Registry already collects these data, but center-level reporting could drive improvement at the local level.

The Role of Patient Advocacy and Support Networks

Patients and families are powerful agents of change. Organizations like the Cystic Fibrosis Foundation, the CFRD Alliance, and local CF chapters provide education, financial assistance, and community connection. Patients can advocate for themselves by asking about diabetes screening at every clinic visit and demanding language-concordant materials. Support networks also help combat the isolation that often accompanies a rare disease. Social media groups and patient-run forums allow individuals to share practical tips for managing CFRD while traveling, working, or facing insurance denials. Healthcare providers should actively promote these resources and partner with patient advocacy groups to design more inclusive services. For example, the CFF’s Community Voice program trains patients to serve on advisory boards that influence research and care delivery priorities.

Looking Ahead: Building Equity into CFRD Care

Reducing disparities in healthcare access for cystic fibrosis diabetes patients is not merely an aspirational goal—it is a clinical imperative. Every missed diagnosis, every delayed insulin prescription, and every untreated exacerbation represents a preventable erosion of lung function and quality of life. We have the tools to do better: telemedicine, culturally competent care models, expanded insurance coverage, and a robust advocacy infrastructure. What remains is the collective will to deploy these resources equitably. By dismantling the socioeconomic, geographic, and systemic barriers that perpetuate inequity, we can build a future where every person with CFRD—regardless of race, income, or zip code—receives the comprehensive, timely care that can prolong their life and expand their possibilities. The Cystic Fibrosis Foundation’s Health Equity initiative, launched in 2023, is a promising step, committing resources to identify and close disparities. Clinical teams, researchers, policymakers, and patients must sustain this momentum. Only then will the promise of advanced CF therapies truly extend to all who need them.